REGENXBIO Inc. (RGNX) stock
RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.24−0.08 (-1.09%)
Close on Nov 17, 2026Market cap $477.94MP/E –Yield –
Regenxbio EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Regenxbio's EV/EBITDA was 3.2× on Jan 31, 2023, against 14.7× a year earlier. Over the last 2 years it ranged from 1.0× to 39.5×, with a median of 14.1×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Jan 31, 2023 | 3.2× | +0.2 |
| 2022 | Dec 30, 2022 | 3.0× | −11.6 |
| 2019 | Apr 30, 2019 | 14.7× | +0.5 |
| 2018 | Dec 31, 2018 | 14.1× | – |
See a number that looks wrong?